Lipid nanoparticles as scaffolds for multispecific cell engagers in autoimmune diseases
Lipid nanoparticles serve as innovative scaffolds for creating multispecific cell engagers to precisely modulate immune responses in autoimmune diseases. These nanoparticles can be engineered for targeted tissue delivery and immune signaling control.
Overview
Lipid nanoparticles offer a groundbreaking approach to developing multispecific cell engagers for autoimmune diseases. By leveraging the unique properties of lipid nanoparticles, these engagers can precisely modulate immune responses. The technology allows for the creation of nanoparticles that either redirect T cells to eliminate immune cells causing autoimmune responses or tune down overactive immune cells, akin to a reverse artificial antigen-presenting cell.
Technical specifications
Key features:
- Utilizes lipid nanoparticles as scaffolds for combining multiple antibodies and proteins.
- Tunable binding avidity through protein stoichiometry for precise immune signaling control.
- Capability to mimic spatial organization of immune receptors for enhanced signaling.
- Engineering of lipid composition to target specific tissues, improving therapeutic delivery.
Applications:
- Redirecting T cells to address autoimmune-triggering cells.
- Modulating immune responses to reduce activity of T and NK cells.
Technology readiness level
The technology is currently at TRL 3, indicating experimental proof of concept. Ongoing research aims to validate targeting strategies and immune modulation in vitro, with plans for in vivo studies. Strategic partnerships are sought to help identify target indications, provide funding, and support further development.
About Lawrence Livermore National Laboratory
Lawrence Livermore National Laboratory is a U.S. Department of Energy national security laboratory in California, operating at scale across integrated science and engineering. Industry collaborates through an open campus that pairs unclassified labs and demo space with proximity to secure facilities, enabling work with staff scientists and access to high‑performance computing and large‑scale testbeds. Engagement options include CRADAs, Strategic Partnership Projects, and other work‑for‑others mechanisms, with flexible IP and data rights to support joint development and rapid prototyping. Research is funded primarily by the Department of Energy and the National Nuclear Security Administration, with additional support from other U.S. agencies; a technology transfer office manages IP, licensing, and startup engagements.
delivered to your inbox.